Literature DB >> 24997685

The discovery of indole full agonists of the neurotensin receptor 1 (NTSR1).

Paolo Di Fruscia1, Yuanjun He1, Marcel Koenig1, Sahba Tabrizifard1, Ainhoa Nieto1, Patricia H McDonald1, Theodore M Kamenecka2.   

Abstract

Neurotensin (NT) is an endogenous tridecapeptide found in the central nervous system (CNS) and in peripheral tissues. Neurotensin exerts a wide range of physiological effects and it has been found to play a critical role in a number of human diseases, such as schizophrenia, Parkinson's disease and drug addiction. The discovery of small-molecule non-peptide neurotensin receptor (NTSR) modulators would represent an important breakthrough as such compounds could be used as pharmacological tools, to further decipher the cellular functions of neurotensin, and potentially as therapeutic agents to treat human disease. Herein, we report the identification of non-peptide low-micromolar neurotensin receptor 1 (NTSR1) full agonists, discovered through structural optimization of the known NTSR1 partial agonist 1. In vitro cellular screenings, based on an intracellular Ca(2+) mobilization assay, revealed our best hit molecule 8 (SR-12062) to have an EC50 of 2 μM at NTSR1 with full agonist behaviour (Emax=100%), showing a higher efficacy and ∼90-fold potency improvement compared to parent compound 1 (EC50=178 μM; Emax=17%).
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Indole agonists; Neurotensin; Neurotensin agonists; Neurotensin receptors; SR-12062

Mesh:

Substances:

Year:  2014        PMID: 24997685      PMCID: PMC4130903          DOI: 10.1016/j.bmcl.2014.06.033

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  28 in total

Review 1.  Targeting neurotensin receptors with agonists and antagonists for therapeutic purposes.

Authors:  Patrick Kitabgi
Journal:  Curr Opin Drug Discov Devel       Date:  2002-09

2.  The identification of neurotensin NTS1 receptor partial agonists through a ligand-based virtual screening approach.

Authors:  Yi Fan; Margaret H Lai; Kelly Sullivan; Michael Popiolek; Terrance H Andree; Paul Dollings; Mark H Pausch
Journal:  Bioorg Med Chem Lett       Date:  2008-09-24       Impact factor: 2.823

Review 3.  Neurotensin and neurotensin receptors.

Authors:  J P Vincent; J Mazella; P Kitabgi
Journal:  Trends Pharmacol Sci       Date:  1999-07       Impact factor: 14.819

4.  Imidazole-derived agonists for the neurotensin 1 receptor.

Authors:  Paul M Hershberger; Michael P Hedrick; Satyamaheshwar Peddibhotla; Arianna Mangravita-Novo; Palak Gosalia; Yujie Li; Wilson Gray; Michael Vicchiarelli; Layton H Smith; Thomas D Y Chung; James B Thomas; Marc G Caron; Anthony B Pinkerton; Lawrence S Barak; Gregory P Roth
Journal:  Bioorg Med Chem Lett       Date:  2013-11-21       Impact factor: 2.823

5.  Discovery of ML314, a Brain Penetrant Non-Peptidic β-Arrestin Biased Agonist of the Neurotensin NTR1 Receptor.

Authors:  Satyamaheshwar Peddibhotla; Michael P Hedrick; Paul Hershberger; Patrick R Maloney; Yujie Li; Monika Milewski; Palak Gosalia; Wilson Gray; Alka Mehta; Eliot Sugarman; Becky Hood; Eigo Suyama; Kevin Nguyen; Susanne Heynen-Genel; Stefan Vasile; Sumeet Salaniwal; Derek Stonich; Ying Su; Arianna Mangravita-Novo; Michael Vicchiarelli; Gregory P Roth; Layton H Smith; Thomas D Y Chung; Glen R Hanson; James B Thomas; Marc G Caron; Lawrence S Barak; Anthony B Pinkerton
Journal:  ACS Med Chem Lett       Date:  2013-07-20       Impact factor: 4.345

Review 6.  The role of neurotensin in physiologic and pathologic processes.

Authors:  W Conan Mustain; Piotr G Rychahou; B Mark Evers
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2011-02       Impact factor: 3.243

7.  A novel stroke therapy of pharmacologically induced hypothermia after focal cerebral ischemia in mice.

Authors:  Ko-Eun Choi; Casey L Hall; Jin-Mei Sun; Ling Wei; Osama Mohamad; Thomas A Dix; Shan P Yu
Journal:  FASEB J       Date:  2012-03-29       Impact factor: 5.191

8.  Design and structure-activity relationships of C-terminal cyclic neurotensin fragment analogues.

Authors:  A M Sefler; J X He; T K Sawyer; K E Holub; D O Omecinsky; M D Reily; V Thanabal; H C Akunne; W L Cody
Journal:  J Med Chem       Date:  1995-01-20       Impact factor: 7.446

9.  Compared binding properties of 125I-labeled analogues of neurotensin and neuromedin N in rat and mouse brain.

Authors:  G Gaudriault; N Zsürger; J P Vincent
Journal:  J Neurochem       Date:  1994-01       Impact factor: 5.372

10.  Neuroprotective effect of the neurotensin analogue JMV-449 in a mouse model of permanent middle cerebral ischaemia.

Authors:  Lars Torup; Jeanett Borsdal; Thomas Sager
Journal:  Neurosci Lett       Date:  2003-11-20       Impact factor: 3.046

View more
  3 in total

1.  Discovery of β-Arrestin Biased, Orally Bioavailable, and CNS Penetrant Neurotensin Receptor 1 (NTR1) Allosteric Modulators.

Authors:  Anthony B Pinkerton; Satyamaheshwar Peddibhotla; Fusayo Yamamoto; Lauren M Slosky; Yushi Bai; Patrick Maloney; Paul Hershberger; Michael P Hedrick; Bekhi Falter; Robert J Ardecky; Layton H Smith; Thomas D Y Chung; Michael R Jackson; Marc G Caron; Lawrence S Barak
Journal:  J Med Chem       Date:  2019-08-20       Impact factor: 7.446

2.  A marine analgesic peptide, Contulakin-G, and neurotensin are distinct agonists for neurotensin receptors: uncovering structural determinants of desensitization properties.

Authors:  Hee-Kyoung Lee; Liuyin Zhang; Misty D Smith; Aleksandra Walewska; Nadeem A Vellore; Riccardo Baron; J Michael McIntosh; H Steve White; Baldomero M Olivera; Grzegorz Bulaj
Journal:  Front Pharmacol       Date:  2015-02-10       Impact factor: 5.810

3.  Complexes of the neurotensin receptor 1 with small-molecule ligands reveal structural determinants of full, partial, and inverse agonism.

Authors:  Mattia Deluigi; Alexander Klipp; Christoph Klenk; Lisa Merklinger; Stefanie A Eberle; Lena Morstein; Philipp Heine; Peer R E Mittl; Patrick Ernst; Theodore M Kamenecka; Yuanjun He; Santiago Vacca; Pascal Egloff; Annemarie Honegger; Andreas Plückthun
Journal:  Sci Adv       Date:  2021-01-27       Impact factor: 14.136

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.